Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ArriVent BioPharma, Inc. Common Stock (AVBP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: AVBP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Analysis of Past Performance
Type Stock | Historic Profit 2.01% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 613.31M USD | Price to earnings Ratio - | 1Y Target Price 39.29 |
Price to earnings Ratio - | 1Y Target Price 39.29 | ||
Volume (30-day avg) 204499 | Beta - | 52 Weeks Range 14.35 - 36.37 | Updated Date 04/2/2025 |
52 Weeks Range 14.35 - 36.37 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.56 |
Earnings Date
Report Date 2025-03-27 | When - | Estimate -0.7814 | Actual -0.61 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -26.91% | Return on Equity (TTM) -39.36% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 394625031 | Price to Sales(TTM) - |
Enterprise Value 394625031 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 34016200 | Shares Floating 15838962 |
Shares Outstanding 34016200 | Shares Floating 15838962 | ||
Percent Insiders 9.72 | Percent Institutions 84.55 |
Analyst Ratings
Rating 4.8 | Target Price 38 | Buy 1 | Strong Buy 4 |
Buy 1 | Strong Buy 4 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
ArriVent BioPharma, Inc. Common Stock
Company Overview
History and Background
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines for the treatment of cancer. Founded in 2021, it focuses on licensing and developing oncology assets, primarily in China, for global markets.
Core Business Areas
- Drug Development: Focused on developing targeted therapies and immuno-oncology agents for various cancer types.
- Licensing and Partnerships: Acquiring rights to promising oncology assets from other companies, particularly those already showing promise in the Chinese market.
Leadership and Structure
Bing Yao, Ph.D., is the CEO. The company has a board of directors and a management team overseeing clinical development, regulatory affairs, and commercial strategy.
Top Products and Market Share
Key Offerings
- Furmonertinib: A novel EGFR inhibitor. Currently in clinical development in various geographies, aiming to improve treatment outcomes for patients with non-small cell lung cancer (NSCLC). Competitors include Tagrisso (AstraZeneca), and other EGFR inhibitors.
Market Dynamics
Industry Overview
The oncology market is experiencing rapid growth, driven by an aging population, advancements in cancer diagnostics and therapies, and increased awareness of cancer prevention and treatment. Significant innovation, including targeted therapies and immunotherapies, is shaping the landscape.
Positioning
ArriVent BioPharma is positioning itself as a player in the targeted therapy space, focusing on acquiring and developing promising assets from the Chinese market and bringing them to global markets. It aims to address unmet needs in cancer treatment.
Total Addressable Market (TAM)
The global oncology market is estimated at hundreds of billions of dollars. ArriVent aims to capture a portion of this TAM by developing and commercializing innovative cancer therapies. Their positioning around EGFR inhibitors and other novel targets allows them to participate in a significant and growing segment of the market.
Upturn SWOT Analysis
Strengths
- Experienced leadership team
- Focus on innovative oncology therapies
- Strategic partnerships for licensing assets
- Strong clinical development pipeline
Weaknesses
- Limited commercial infrastructure
- Dependence on licensing agreements
- Clinical trial risks
- Limited product diversification
Opportunities
- Expansion into new markets
- Strategic acquisitions of promising assets
- Advancements in cancer diagnostics and personalized medicine
- Partnerships with larger pharmaceutical companies
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and changing healthcare policies
- Clinical trial failures
- Intellectual property disputes
Competitors and Market Share
Key Competitors
- AZN
- MRK
- BMY
- PFE
Competitive Landscape
ArriVent is a smaller player competing against established pharmaceutical companies with deeper pockets and more diversified portfolios. Its competitive advantage lies in its focus on licensing and developing promising oncology assets from the Chinese market.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Limited historical growth data as a recently founded company.
Future Projections: Future growth will depend on the successful development and commercialization of its pipeline assets. Analyst estimates are subject to change based on clinical trial results and regulatory milestones.
Recent Initiatives: Recent initiatives include advancing clinical trials for Furmonertinib and exploring new licensing opportunities.
Summary
ArriVent BioPharma is a newly formed company with an experienced team and a pipeline of promising oncology assets. Its strategy of licensing assets from China has the potential to yield significant returns, but it faces risks related to clinical trial outcomes and competition from larger pharmaceutical companies. The company's success hinges on its ability to navigate the regulatory landscape and successfully commercialize its therapies. Given its status, risks are high, but so is the potential reward.
Similar Companies
AZN
AstraZeneca PLC ADR
AZN
AstraZeneca PLC ADR
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
MRK
Merck & Company Inc
MRK
Merck & Company Inc
PFE
Pfizer Inc
PFE
Pfizer Inc
Sources and Disclaimers
Data Sources:
- Company website
- Public filings
- Analyst reports
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ArriVent BioPharma, Inc. Common Stock
Exchange NASDAQ | Headquaters Newtown Square, PA, United States | ||
IPO Launch date 2024-01-26 | Co-Founder, Chairman, President & CEO Dr. Zhengbin Yao Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 52 | Website https://arrivent.com |
Full time employees 52 | Website https://arrivent.com | ||
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.